Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07695779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

QT Interval Effects Study of Oral FXS5626 Tablets

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Study completion pushed from Sep 25, 2026 to Jan 22, 2027
    • Primary completion date changed from estimate of Sep 25, 2026 to Sep 21, 2026
    • Start date changed from estimate of Aug 5, 2026 to Aug 13, 2026
    • Eligibility criteria expanded, about 15 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc interval of a single oral dose of FXS5626 in healthy subjects.
Trial Details
NCT Number NCT07695779
Lead Sponsor Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions
(from sponsor)		 Evaluation of QTc Interval
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov